hVIVO plc (LON:HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, has announced that it will release its final results for the year ended 31 December 2024 on Thursday 10 April 2025.
Analyst briefing
A briefing open to equity research analysts will take place on Thursday 10 April 2025 at 11.00am BST. To register and for more details please contact Walbrook PR on [email protected].
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.
